FTRE vs SPTX
FTRE: Fortrea is a dedicated global CRO focused on clinical trial execution and commercialization services to help biopharmaceutical companies bring new therapies to market. SPTX: Seaport Therapeutics is a clinical-stage biopharmaceutical company advancing a pipeline of novel therapeutics using its proprietary drug development platform.
Side-by-side fundamentals
| Metric | FTRE | SPTX | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $19.17 | $20.46 | |
| Market cap as of 2026-08-03 | $1.8B | $1.1B | |
| PEG as of 2026-08-03 | 0.45 | n/a | |
| Net margin as of 2026-08-03 | -16.5% | n/a | |
| Gross margin as of 2026-08-03 | +18.9% | n/a | |
| Operating margin as of 2026-08-03 | -13.1% | n/a | |
| ROE as of 2026-08-03 | -79.1% | -24.2% | SPTX higher |
| ROA as of 2026-08-03 | -16.3% | -22.6% | FTRE higher |
| Debt / equity as of 2026-08-03 | 2.00 | 0.00 | SPTX lower |
| Revenue growth (YoY) as of 2026-08-03 | +0.9% | n/a | |
| Revenue CAGR (3y) SEC XBRL | -1.4% | n/a | |
| Beta as of 2026-08-03 | 1.82 | -1.43 | |
| 1-year return as of 2026-07-31 close | +234.0% | n/a |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.